Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
The deal expands Sanofi's immunology pipeline and access to drugs to treat systemic mastocytosis (SM), a rare immunological disease.
Sanofi CEO Paul Hudson said that the French company "still retains a sizeable capacity for further acquisitions."French drugmaker Sanofi (SNY) said Monday it has agreed to acquire Blueprint Medicines (BPMC) for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in in intraday trading.
The deal expands Sanofi's immunology pipeline and access to drugs to treat systemic mastocytosis (SM), a rare immunological disease, and "other KIT-driven diseases," the company said. Sanofi also noted that the acquisition would give it access to rare immunology disease medicine avapritinib, marketed as Ayvakit or Ayvakyt, which has been approved in the U.S. and the European Union (EU).
"The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios," Sanofi CEO Paul Hudson said, adding that the French company "still retains a sizeable capacity for further acquisitions."
Under the terms of the Blueprint transaction, Sanofi will pay $129.00 per share in cash or $9.1 billion as well as potential milestone payments. The deal is the latest by the French pharma giant, which last month agreed to buy Alzheimer's disease drug developer Vigil Neuroscience (VIGL).
Sanofi shares were down slightly Monday but are up 2% year-to-date through Friday. Blueprint shares are gaining 26% in intraday trading and have risen 16% entering Monday.
UPDATE—June 2, 2025: This article has been updated to include refreshed share prices.
Read the original article on Investopedia
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
7 hours ago
- Business Insider
Analysts Are Neutral on Top Healthcare Stocks: Bausch Health Companies (BHC), Sanofi (SNYNF)
Analysts fell to the sidelines weighing in on Bausch Health Companies (BHC – Research Report) and Sanofi (SNYNF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bausch Health Companies (BHC) TD Cowen analyst Michael Nedelcovych maintained a Hold rating on Bausch Health Companies yesterday and set a price target of $7.00. The company's shares closed last Friday at $5.71. According to Nedelcovych has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.8% and a 27.9% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Takeda Pharmaceutical Company, Molecular Partners AG, and Coherus Biosciences. Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $8.33, implying a 44.1% upside from current levels. In a report issued on July 25, Truist Financial also maintained a Hold rating on the stock with a $6.78 price target. Sanofi (SNYNF) Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 31 and set a price target of EUR95.00. The company's shares closed last Friday at $92.56, close to its 52-week low of $88.90. According to Pauillac is ranked #974 out of 9914 analysts. Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $127.69, implying a 38.0% upside from current levels. In a report issued on July 17, Deutsche Bank also maintained a Hold rating on the stock with a EUR100.00 price target.
Yahoo
17 hours ago
- Yahoo
Mistral in talks with VC firms, MGX to raise funds at $10 billion valuation, FT reports
(Reuters) -French artificial intelligence startup Mistral is in talks with investors, venture capital firms and Abu Dhabi's MGX to raise $1 billion at a valuation of $10 billion, the Financial Times reported on Friday, citing people familiar with the matter. The company launched in June Europe's first AI reasoning model, which uses logical thinking to create a response, as it tries to keep pace with American and Chinese rivals at the forefront of AI development. The funding would accelerate the commercial rollout of Mistral's Le Chat chatbot and support continued development of its large language models, the report said. MGX and Mistral did not immediately respond to Reuters requests for comment. The startup raised 600 million euros in a Series B funding round that valued the company at 5.8 billion euros last year. Industry observers consider Mistral as Europe's best-positioned AI company to rival Silicon Valley leaders, though the French firm has yet to achieve comparable market traction or revenue scale. Mistral counts Nvidia, Andreessen Horowitz and Lightspeed Venture Partners among its investors. Sign in to access your portfolio
NBC Sports
20 hours ago
- NBC Sports
Novak Djokovic among investors to buy a stake in second-tier French soccer club Le Mans
LE MANS, France — Novak Djokovic is part of a group of investors who have bought a stake in French second-tier soccer team Le Mans, along with ex-Formula 1 drivers Felipe Massa and Kevin Magnussen. Le Mans said in a statement that they join other new financial investors into the club, including Latin American sports investment firm OutField and Georgios Frangulis, the founder and chief executive of OakBerry. Frangulis is the boyfriend of three-time women's Grand Slam champion Aryna Sabalenka. 'The uniqueness of this fund also lies in its contribution from high-level athletes,' Le Mans president Thierry Gomez said in the statement. 'Novak Djokovic, Felipe Massa, and Kevin Magnussen will be part of the adventure.' No financial details were given. Djokovic is the owner of a men's record 24 Grand Slam titles in tennis. The 38-year-old Serb has won 100 career titles overall. Massa won 11 races and secured 41 podiums in his F1 career. When driving for Ferrari, the popular Brazilian was within a whisker of winning the 2008 title, only for Lewis Hamilton to beat him in a dramatic finish at the last race. Hamilton won the title by 98 points to 97. The 32-year-old Magnussen drove close to 200 races in F1, securing one podium and one pole position. But the Danish driver was not retained by Haas when his contract expired. Le Mans soccer club, which is celebrating its 40th anniversary, begins its league campaign on Aug. 9. Le Mans — a small city in northwestern France — also hosts the famed 24-hour endurance car race.
